CRVS · Corvus Pharmaceuticals, Inc.
$14.10
-0.80 (-5.37%)
At close · Jul 20
Market Cap
$1.19B
Shares
84.09M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| Investor Event Transcript | 2026-06-30 | — | |
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-06-12 | 2026-06-11 | |
| 8-K | 2026-05-14 | — | |
| 8-K | 2026-05-07 | — | |
| 10-Q | 2026-05-07 | 2026-03-31 | |
| DEF 14A | 2026-04-24 | 2026-06-11 | |
| 8-K | 2026-04-23 | 2026-04-22 | |
| 8-K | 2026-03-13 | — | |
| 8-K | 2026-03-12 | — | |
| 10-K | 2026-03-12 | 2025-12-31 | |
| 8-K | 2026-01-23 | 2026-01-21 | |
| 8-K | 2026-01-20 | — | |
| 8-K | 2026-01-20 | — | |
| 8-K | 2025-11-04 | — | |
| 10-Q | 2025-11-04 | 2025-09-30 | |
| 8-K | 2025-10-02 | — | |
| 10-Q | 2025-08-07 | 2025-06-30 | |
| 8-K | 2025-08-07 | — | |
| 8-K | 2025-06-13 | 2025-06-12 | |
| 8-K | 2025-06-04 | — | |
| 10-Q | 2025-05-08 | 2025-03-31 | |
| 8-K | 2025-05-08 | — | |
| DEF 14A | 2025-04-25 | 2025-06-12 | |
| 8-K | 2025-04-09 | 2025-04-08 | |
| 8-K | 2025-03-25 | — | |
| 10-K | 2025-03-25 | 2024-12-31 | |
| 8-K | 2025-01-13 | — | |
| 8-K | 2024-12-18 | — | |
| 10-Q | 2024-11-12 | 2024-09-30 | |
| 8-K | 2024-11-12 | — | |
| 8-K | 2024-10-23 | 2024-10-22 | |
| 10-Q | 2024-08-06 | 2024-06-30 | |
| 8-K | 2024-08-06 | — | |
| 8-K | 2024-06-14 | 2024-06-13 | |
| 10-Q | 2024-05-07 | 2024-03-31 | |
| 8-K | 2024-05-06 | 2024-05-01 | |
| 8-K | 2024-05-06 | — | |
| 8-K | 2024-05-01 | — | |
| DEF 14A | 2024-04-26 | 2024-06-13 | |
| 8-K | 2024-03-19 | — | |
| 10-K | 2024-03-19 | 2023-12-31 | |
| 8-K | 2024-01-23 | — | |
| 10-Q | 2023-11-07 | 2023-09-30 | |
| 8-K | 2023-11-07 | — | |
| 8-K | 2023-09-07 | 2023-09-06 | |
| 8-K | 2023-08-08 | — | |
| 10-Q | 2023-08-08 | 2023-06-30 | |
| 8-K | 2023-06-21 | 2023-06-15 | |
| 8-K | 2023-05-08 | — |
Showing 1–50 of 108 filings
Key facts
CIK
1626971
CUSIP
221015100
13F (30d)
10 filings
10 filers
Visit website
Investor relations